Hugel said it obtained product approval from the French drug ministry (Agence Nationale de Sécurité du Médicament) for Letybo, its botulinum toxin formulation, for treating forehead wrinkles last Thursday.The approval follows Hugel receiving a recommendation for approval of the product approval for
SK Plasma said that it has signed a contract with Khairi S.A., a South American pharmaceutical sales company, to export 38.4 billion won ($31.8 million) of blood products.Under the accord, Khairi will have the right to supply SK Plasma's blood products, such as LIV-r Inj. and albumin, to eight count
Samsung Biologics said Friday that it had decided to acquire all 10,341,852 shares of Samsung Bioepis owned by Biogen, a multinational pharmaceutical company, for $2.3 billion.After Biogen requested Samsung Biologics to buy out their shares, the two companies finalized the deal.Biogen had owned 50 p
The Korea Health Industry Development Institute (KHIDI) said Thursday that it would recruit companies to move into the C&D Incubation Center located in Boston CIC (Cambridge Innovation Center), the U.S., from Thursday to Feb. 11.It is part of the government’s “K-Blockbuster Support Project,” which a
A joint research team has released a short-term clinical result confirming the efficacy of Novartis' gene therapy Zolgensma (ingredient: onasemnogene abeparvovec) in treating Korean patients with spinal muscular atrophy (SMA).The real-world evidence (RWE) study, published in the online edition of Br
AbbVie said its drug Skyrizi (ingredient: risankizumab) obtained the U.S. FDA authorization to treat adults with active psoriatic arthritis (PsA).The FDA approval was based on the results of the KEEPsAKE-1 and KEEPsAKE-2 trials which tested Skyrizi in adults with PsA, including those who had respond
Hanmi Pharmaceutical is busy preparing for a market release of inhaled asthma medication, Glyterol Inhalation Cap. 110/50 μg.As the original drug's patent expired partially, industry officials are closely watching when Hanmi will release Glyterol.The Ministry of Food and Drug Safety said Hanmi’s Gly
After 14 months of collaboration, SK Chemicals and Dr. Noah Biotech succeeded in deriving three new drug candidates to treat nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IDF) using artificial intelligence.The two companies stressed that their results have proved AI technolo
Celltrion and Icure Pharmaceutical have registered a pharmaceutical patent on a “patch-type dementia treatment,” preparing to release the product in Korea within the first half of this year.The Ministry of Food and Drug Safety (MFDS) said the two companies registered the patent on the donepezil-cont
Hugel said that the EU's Heads of Medicines Agencies (HMA) has issued a positive opinion for the approval of Letybo, its botulinum toxin (BTX) product, for treating forehead wrinkles.HMA is an association of drug safety management organizations in each European country.The company expects to enter i
Eutilex signed an MOU with Medirama, specializing in clinical consulting, to develop and commercialize strategic new drugs.The two companies will maximize synergy in the overall development of new drugs, such as discovering additional candidates for Eutilex’s cell therapy and dual antibody therapy,
Kyongbo Pharm said Tuesday it recently obtained approval from the Ministry of Food and Drug Safety for DPP-4 antidiabetic drugs Vilda Tab. and Vildamet Tab.Four products got the marketing approval – one monotherapy using vildagliptin as the main ingredient and three doses of Vilda Tab. plus metformi
Ripretinib (brand name: Qinlock), developed by Deciphera Pharmaceuticals as a treatment for gastrointestinal stromal tumors (GIST), failed to improve progression-free survival (PFS) in advanced GIST patients, compared to sunitinib (brand name: Sutent).However, ripretinib showed favorable data in adv
Boehringer Ingelheim and Boryung Pharmaceutical have terminated their joint marketing partnership of Pradaxa (ingredient: dabigatran), a new oral anticoagulant (NOAC).According to the pharmaceutical industry on Monday, the two companies ended their co-promotion contract last year-end.Pradaxa is a NO
BMS is getting ready to tap the psoriasis treatment market with a novel, oral, tyrosine kinase 2 (TYK2) inhibitor, which averted the safety risk of the existing Janus kinase (JAK) inhibitors.At the 40th Annual JP Morgan Healthcare Conference, BMS introduced the first TYK2 inhibitor deucravacitinib,
“As policies, financial support, and regulations for pharmaceutical and biotech industry growth are dispersed across multiple government agencies, the efficiency has been lowered. And no entity manages the entire cycle of new drug development, from basic research to clinical trials and global expans
Chong Kun Dang, which released overactive bladder treatment Selebeta SR Tab. 25mg (mirabegron) last year, recently registered a drug patent to the Ministry of Food and Drug Safety.As Chong Kun Dang is the only local drugmaker selling a low-dose generic drug of Betmiga, the initial therapy by Astella
Handok Pharmaceuticals said it obtained the U.S. FDA approval to conduct a phase 2 clinical trial of ABL001 (CTX-009), an investigational anticancer treatment the Korean company is jointly developing with Compass Therapeutics.The FDA nod is meaningful particularly because the local phase 2 study of
Boryung Pharmaceutical said that it has signed a sales contract with Almirall for Finjuve, a spray-type finasteride-based hair loss treatment, in Korea.The agreement will give Boryung exclusive sales rights for Finjuve in Korea.Finjuve, developed by Almirall, a global pharmaceutical company, is the
Hanmi Pharmaceutical and Celltrion said they would manufacture Lagevrio pills, low-cost version of Merck’s Covid-19 treatment molnupiravir, and supply them to 105 low- and-middle-income countries.The Medicines Patent Pool (MPP) has chosen 27 drugmakers, including the two Korean companies, to make an